Bobby Sandage
General Partner @ Cultivation Capital
St Louis, United States
Bobby Sandage is a Series A investor at Cultivation Capital in St Louis focused on Genetics and Health Care. Dr. Bobby Sandage is the Managing Director of Paula and Rodger Riney Foundation. He is also a General Partner at Cultivation Capital and the President and CEO of Euclises Pharmaceuticals. Dr. Bobby Sandage most recently was President and CEO and member of the board for Coronado BioSciences, Inc. (CNDO) from March 2011 to April 2013. Previously, hewas vice president of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program from March 2010 to March 2011. From 1991 until 2009 (when Endo Pharmaceuticals acquired Indevus), Dr. Sandage was the Chief Scientific Officer and executive vice president of research and development, quality and manufacturing at Indevus Pharmaceuticals. He previously held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. Dr. Sandage received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas. Dr. Sandage is also a registered pharmacist.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Bobby Sandage invests in
Stages Bobby Sandage invests in
Countries Bobby Sandage invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Genetics 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M / Series B / Nov 16, 2021 | ||
| Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M / Series A / Oct 02, 2019 |
Co-Investors
About Cultivation Capital
Cultivation Capital is a venture capital firm that manages a family of funds focused on early-stage investing. Most of our initial investments are during a startup’s Seed or Series A phase, and our initial checks range from $500k – $3.5M. Our industries of focus include life sciences and health tech, software and IT, agriculture tech, andgeospatial tech.
Cultivation Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alana Mann
Principal
|
|||
Andy Dearing
General Partner
|
|||
Brian Matthews
Co-Founder & General Partner
|
|||
David Smoller
General Partner - Life Sciences Fund
|
|||
Dean VandeKamp
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bobby Sandage invest in?
Bobby Sandage invests primarily in Genetics, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bobby Sandage?
Public channels for Bobby Sandage include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bobby Sandage last invest?
The most recent investment recorded for Bobby Sandage closed in Nov 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
